Hypersomnias

SomnusNooze Articles > Hypersomnias


Act Today and Let Your Voice Be Heard

Very recently, the Hypersomnia Foundation became aware of an opportunity to help shape the future of sleep research. The National Institutes of Health, the primary source of funding for medical research in the United States, has issued a Request for Information, which you can view at: https://grants.nih.gov/grants/guide/notice-files/NOT-HL-16-312.html. The final date to...

Continue Reading

Sleep-Wake Disturbance Following a Traumatic Brain Injury

Background According to the Centers for Disease Control and Prevention (CDC), more than 2 million people in the United States suffer a traumatic brain injury (TBI) every year. Most people with a TBI will also experience a sleep-wake disturbance (a real or perceived change in night-time sleep with resulting daytime...

Continue Reading

What Does One SOREMP Mean?

Background The primary feature of the two main central disorders of hypersomnolence—narcolepsy and idiopathic hypersomnia (IH)—is excessive daytime sleepiness, defined in the International Classification of Sleep Disorders, third edition, as “daily episodes of an irrepressible need to sleep or daytime lapses into sleep." Overnight sleep testing (polysomnography) and a...

Continue Reading

Summary of Rationale Behind and Research Studies into L-carnitine as a Treatment for Narcolepsy

Background In this 2013 study published in PLoS One, the researchers Miyagawa et al hypothesized that L-carnitine supplementation might help improve narcolepsy symptoms by increasing β-fatty-acid oxidation. Fatty acids are a major energy source for the human body. For them to be broken down and metabolized via oxidation...

Continue Reading

EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy

On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In making its recommendation, the Committee reviewed data from four studies of pitolisant—two placebo-controlled...

Continue Reading

A Comparison of Sodium Oxybate in the Treatment of Idiopathic Hypersomnia and Narcolepsy Type 1

Background Sodium oxybate (SXB) is a drug sold as Xyrem in the United States by Jazz Pharmaceuticals, in Europe by UCB Pharma, and in Canada by Valeant Pharmaceuticals. It is approved in the United States in adults for the treatment of excessive daytime sleepiness (EDS) and...

Continue Reading

Does Excessive Daytime Sleepiness Affect Children’s Pedestrian Safety?

Background Each year, approximately 30,000 children are unintentionally killed or injured while walking outside (typically within a half mile of their homes). Many factors—including children’s thinking and reasoning abilities, attention spans, reaction times, impulsiveness, and willingness to take risks—likely play a role. Excessive daytime sleepiness (EDS),...

Continue Reading

The Hypersomnia Foundation Welcomes New Board Members

We are pleased to announce that Scot Hulshizer, Celia King, and Diane Powell have recently been elected to the Board of Directors of the Hypersomnia Foundation. In addition to bringing unique strengths as the organization thrives and grows in both scope and depth, each new Board...

Continue Reading

Get SomnusNooze, our e-newsletter

Sign up to receive HF updates, news from the world of sleep research, first-person stories, and more.

You will receive and email from (please check your junk/spam folder if needed) to confirm your subscription to our newsletter through MailChimp. You are not subscribed until you confirm. Thank you for your interest in Hypersomnia Foundation!